The secondary endpoint and exploratory analysis of the study by Cavas et al. indicated that SGLT-2 inhibitors can reduce the risk of new-onset nephropathy [13], suggesting that such drugs have a promising application to the primary prevention of nephropathy; however, direct evidence remains lacking. This evidence concerns the gene SLC5A2 and kidney disorder.